Source BBC: A new treatment for patients with multiple sclerosis has been approved by the Scottish Medicines Consortium (SMC).
Zeposia has been developed for adult patients with relapsing-remitting MS, where the patient has flare-ups followed by periods of remission.
It is a treatment option which may reduce the need to have treatment administered in a clinical setting.
It is one of four drugs which have been newly-approved.
Ozanimod – Zeposia is manufactured by the company Bristol Myer Squibb. Taken orally once a day it provides the advantage of being taken at home and avoiding clinical appointments during the coronavirus pandemic. Read on.